<DOC>
	<DOCNO>NCT01454986</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , PK PD single-dose ALXN1007 healthy volunteer .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , PK PD ALXN1007 Healthy Subjects</brief_title>
	<detailed_description>All subject screen eligibility provide sign informed consent . Once subject determine eligible , subject vaccinate quadrivalent meningococcal conjugate vaccine least two week prior dose , applicable . A total 7 dose cohort enrol sequentially randomize receive ALXN1007 placebo . Subjects receive ALXN1007 placebo clinic keep clinic total 4 day observation completion require study test . The subject return 8 additional clinic visit complete require study test next 86 day . The total duration study 90 day day dose ALXN1007 placebo .</detailed_description>
	<criteria>Healthy individual 25 55 year age document vaccination MCV4 . Abnormal renal liver function . History meningococcal disease . History GuillainBarre syndrome . Known infection HIV Hepatitis B C .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Healthy subject</keyword>
</DOC>